Gyre Therapeutics, Inc. (GYRE)’in fiyatı nedir?

Gyre Therapeutics, Inc. (GYRE)’in fiyatı $6.61’dir

Gyre Therapeutics, Inc. (GYRE)’in piyasa değeri nedir?

Gyre Therapeutics, Inc. (GYRE)’in piyasa değeri $736.94M’dir.

Gyre Therapeutics, Inc. (GYRE) HBK

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

Yıl	EPS	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

EPS

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	EPS	EPS Farkı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Şirket

EPS

EPS Farkı

Ülke